Loading clinical trials...
Loading clinical trials...
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
Conditions
Interventions
Darolutamide (Nubeqa, BAY1841788)
Locations
1
South Korea
Multiple locations
Multiple Locations, South Korea
Start Date
September 25, 2024
Primary Completion Date
March 31, 2028
Completion Date
June 30, 2028
Last Updated
April 14, 2026
NCT06835218
NCT07190300
NCT06991556
NCT07181122
NCT06010914
NCT06479187
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions